Clinical Trial Results:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache
Summary
|
|
EudraCT number |
2015-000149-22 |
Trial protocol |
DE GB DK BE FI ES NL GR |
Global end of trial date |
04 Jun 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Jun 2019
|
First version publication date |
30 Jun 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
I5Q-MC-CGAL
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02397473 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Trial Number: 15780 | ||
Sponsors
|
|||
Sponsor organisation name |
Eli Lilly and Company
|
||
Sponsor organisation address |
Lilly Corporate Center, Indianapolis, IN, United States, 46285
|
||
Public contact |
Available Mon ‐ Fri 9 AM ‐ 5 PM EST, Eli Lilly and Company, 1 877‐CTLilly,
|
||
Scientific contact |
Available Mon ‐ Fri 9 AM ‐ 5 PM EST, Eli Lilly and Company, 1 877‐285‐4559,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
04 Jun 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
04 Jun 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headache.
|
||
Protection of trial subjects |
This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
22 May 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Greece: 3
|
||
Country: Number of subjects enrolled |
Canada: 2
|
||
Country: Number of subjects enrolled |
Netherlands: 3
|
||
Country: Number of subjects enrolled |
Belgium: 8
|
||
Country: Number of subjects enrolled |
United States: 34
|
||
Country: Number of subjects enrolled |
Finland: 3
|
||
Country: Number of subjects enrolled |
Denmark: 3
|
||
Country: Number of subjects enrolled |
Italy: 20
|
||
Country: Number of subjects enrolled |
United Kingdom: 2
|
||
Country: Number of subjects enrolled |
France: 9
|
||
Country: Number of subjects enrolled |
Germany: 6
|
||
Country: Number of subjects enrolled |
Spain: 13
|
||
Worldwide total number of subjects |
106
|
||
EEA total number of subjects |
70
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
104
|
||
From 65 to 84 years |
2
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
Subjects had screening/washout phase for minimum of 0 days to maximum of 12 months. Subjects who enter screening in an active cluster headache (CH) period & meet initial screening eligibility can move directly into baseline phase as long as they do not need to wash out of any excluded medications. Subjects who enter in remission remain in screening | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
until onset of their next CH period.Prospective baseline phase begins on the day that the Subject first records a CH attack in their electronic patient-reported outcome (ePRO) diary. Minimum duration is 10 days of daily ePRO diary recording prior to Visit 3, & the preferred maximum duration is 14 days of daily ePRO diary recording prior to visit 3. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Treatment Phase
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||
Arm description |
Participants received placebo once a month for 2 months by subcutaneous (SC) injection during treatment phase. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Placebo administered subcutaneously once a month for 2 months.
|
||||||||||||||||||||||||||||||
Arm title
|
Galcanezumab 300mg | ||||||||||||||||||||||||||||||
Arm description |
Participants received Galcanezumab 300mg once a month for two months by subcutaneous (SC) injection during treatment phase. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Galcanezumab
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
LY2951742
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
300mg Galcanezumab administered by subcutaneous injection once a month for 2 months.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||
Period 2 title |
Post Treatment Follow-up Phase
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||
Arm description |
Participants did not receive any intervention during post treatment follow-up phase. | ||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||
Arm title
|
Galcanezumab 300mg | ||||||||||||||||||||||||||||||
Arm description |
Participants did not receive any intervention during post treatment follow-up phase. | ||||||||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo once a month for 2 months by subcutaneous (SC) injection during treatment phase. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Galcanezumab 300mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received Galcanezumab 300mg once a month for two months by subcutaneous (SC) injection during treatment phase. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants received placebo once a month for 2 months by subcutaneous (SC) injection during treatment phase. | ||
Reporting group title |
Galcanezumab 300mg
|
||
Reporting group description |
Participants received Galcanezumab 300mg once a month for two months by subcutaneous (SC) injection during treatment phase. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants did not receive any intervention during post treatment follow-up phase. | ||
Reporting group title |
Galcanezumab 300mg
|
||
Reporting group description |
Participants did not receive any intervention during post treatment follow-up phase. |
|
|||||||||||||
End point title |
Overall Mean Change from Baseline in Number of Weekly Cluster Headache Attacks | ||||||||||||
End point description |
Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Overall mean change from baseline is derived from the average of weeks 1 to 3 from mixed model repeated measures (MMRM) analysis. Least Square (LS) means were calculated using MMRM model with treatment, sex, pooled investigative site, week, baseline, and treatment by week as fixed effects.
Analysis Population Description (APD): All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline measurement.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Week 1 through Week 3
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.036 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSMean Difference | ||||||||||||
Point estimate |
-3.47
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-6.72 | ||||||||||||
upper limit |
-0.23 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
1.63
|
|
|||||||||||||
End point title |
Percentage of Participants with 50% or Greater Reduction From Baseline in the Weekly Number of Cluster Headache Attacks | ||||||||||||
End point description |
Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Percentage of participants with 50% or greater reduction from baseline at week 3 was analyzed using Koch's nonparametric randomization-based analysis of covariance method. This method adjusted for pooled investigative site by including it as a stratification variable. It also adjusted for sex and baseline value.
APD: All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline measurement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 3
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Statistical analysis description |
Koch's nonparametric randomization-based ANCOVA.
|
||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.046 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks | ||||||||||||
End point description |
Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Overall mean change from baseline is derived from the average of weeks 1 to 8 from MMRM analysis. Least Square (LS) means were calculated using MMRM model with treatment, sex, pooled investigative site, week, baseline, and treatment by week as fixed effects.
APD:All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline measurement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 1 through Week 8
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.493 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSMean Difference | ||||||||||||
Point estimate |
-0.83
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-3.23 | ||||||||||||
upper limit |
1.57 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
1.2
|
|
|||||||||||||
End point title |
Percentage of Participants Reporting a Score of 1 or 2 on the Patient Global Impression of Improvement (PGI-I) | ||||||||||||
End point description |
PGI-I requests participants to mark the box that best describes their cluster headache condition since they started taking the medicine. The options in the displayed boxes are represented on a 7-point scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Percentage of participants were derived with a generalized linear mixed model repeated measures method with treatment, sex, baseline cluster headache attack category, month, and treatment by month as fixed effects.
APD:All randomized participants who received at least one dose of study drug and had PGI-I measurement at week 4.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 4
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
93
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.016 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
3.046
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.242 | ||||||||||||
upper limit |
7.469 |
|
|||||||||||||
End point title |
Percentage of Participants Reporting a Score of 1 or 2 on the Patient Global Impression of Improvement (PGI-I) | ||||||||||||
End point description |
PGI-I requests participants to mark the box that best describes their cluster headache condition since they started taking the medicine. The options in the displayed boxes are represented on a 7-point scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Percentage of participants were derived with a generalized linear mixed model repeated measures method with treatment, sex, baseline cluster headache attack category, month, and treatment by month as fixed effects.
APD: All randomized participants who received at least one dose of study drug and had PGI-I measurement at week 8.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 8
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.575 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.312
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.502 | ||||||||||||
upper limit |
3.426 |
|
|||||||||||||
End point title |
Percentage of Participants with 50% or Greater Reduction from Baseline in Number of Weekly Cluster Headache Attacks | ||||||||||||
End point description |
Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Mean percentage of participants is derived from the average of weeks 1 to 8 from generalized linear mixed model repeated measures method with treatment, sex, week, treatment by week, and baseline as fixed effects.
APD:All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline measurement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 1 through Week 8
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.91 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.965
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.512 | ||||||||||||
upper limit |
1.819 |
|
|||||||||||||
End point title |
Percentage of Participants with 30% or Greater Reduction from Baseline in Number of Weekly Cluster Headache Attacks | ||||||||||||
End point description |
Number of cluster headache attacks was recorded daily by study participants in their ePRO Diary. Mean percentage of participants is derived from the average of weeks 1 to 8 from generalized linear mixed model repeated measures with treatment, sex, week, treatment by week and baseline as fixed effects.
APD:All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline measurement.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 1 through Week 8
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Galcanezumab 300mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.841 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.929
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.449 | ||||||||||||
upper limit |
1.923 |
|
|||||||||
End point title |
Pharmacokinetics (PK): Serum Concentration of Galcanezumab [1] | ||||||||
End point description |
APD: All randomized participants who received at least one dose of study drug and had measurable PK samples.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 4
|
||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, Statistical analysis was not planned. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetics (PK): Serum Concentration of Galcanezumab [2] | ||||||||
End point description |
APD: All randomized participants who received at least one dose of study drug and had measurable PK samples.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 8
|
||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Per protocol, Statistical analysis was not planned. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab | ||||||||||||
End point description |
Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer >= 1: 20.
APD: All randomized participants who received at least one dose of study drug and had non-missing baseline ADA result, and at least one non-missing post baseline ADA result.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline through Week 8
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants With Suicidal Ideation Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS) | ||||||||||||
End point description |
C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. Some questions are binary responses (yes/no) and some are on a scale of 1 (low severity) to 5 (high severity). Suicidal ideation: a "yes" answer to any of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent.
APD:All randomized participants who received at least one dose of study drug and had at least one post baseline C-SSRS assessment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Month 1 through Month 6
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS) | ||||||||||||
End point description |
C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. Some questions are binary responses (yes/no) and some are on a scale of 1 (low severity) to 5 (high severity). Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.
APD: All randomized participants who received at least one dose of study drug and had at least one post baseline C-SSRS assessment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Month 1 through Month 6
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Entire Study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
I5Q-MC-CGAL
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo - Treatment Phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Galcanezumab 300mg - Treatment Phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo - Post-treatment Phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Galcanezumab 300mg - Post-treatment Phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
22 Dec 2015 |
Revised Inclusion Criteria 9 to allow oral triptans as an abortive medication to align with current clinical practice. |
||
10 Feb 2017 |
Revised Exclusion Criterion 22e (Have any history of intracranial or carotid aneurysm, intracranial hemorrhage, or stroke.) and added Exclusion Criterion 23d (Patients with a history of an intracranial tumor or head trauma must be discussed and judged not to indicate a medical problem that would preclude study participation by Lilly Medical prior to enrollment.) because intracranial or carotid aneurysm, intracranial hemorrhage, and stroke are cardiovascular-related conditions, whereas intracranial tumor and significant head trauma are not cardiovascular related. Patients with either of the non-cardiovascular-related conditions mentioned here may be enrolled in the clinical trial if upon discussion with Lilly Medical it is judged not to indicate a medical problem that would preclude study participation.
Revised exclusion criteria to allow patients who fail eligibility due to an elevation of ≥2X ULN for ALT, or ≥1.5X ULN TBL or ALP to be retested.
Added a new rescreening allowance for Inclusion Criteria to allow patients who fail eligibility due to the occurrence of >8 cluster headache attacks per day
to rescreen for the study during their current cluster headache period.
Added a new rescreening allowance for Exclusion Criteria this change allows patients who fail eligibility due to a positive UDS to be rescreened during their current cluster headache period. |
||
18 Mar 2018 |
Updated the primary endpoint to be the overall treatment effect across Weeks 1 to 3 in weekly cluster headache attack frequency rather than the treatment effect at a single time point (Week 3). |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |